DSM funds a new meta-analysis that only includes studies on high doses of oat beta-glucans.
A soluble fiber in oats, called oat beta-glucan, is widely regarded for its ability to help lower human cholesterol. At least five national health agencies around the world permit related oat beta-glucan health claims. Multiple studies back up these health claims, but DSM Nutritional Products (Parsippany, NJ) realized that of the published meta-analyses available on oat beta-glucan studies, none have been restricted to studies involving 3 g of beta-glucans or more daily-the dosage required for compliance with all oat beta-glucan health claims around the world.
Because DSM has stake in the oat beta-glucan market, the company funded a selective meta-analysis of studies based on the three-gram dosage. The results were still positive-significant reductions in LDL and total cholesterol-but they were, in a way, noticeably different from those of previous investigations.
“Although generally confirming the results of previous meta-analyses, that oat products reduce serum cholesterol, the present results differ in that the magnitude of the effects seen are 50–100% greater than those reported in previous meta-analyses,” said the researchers. DSM says the high dose of oat beta-glucan allows this compound to escape the food matrix once it is consumed, which allows it to form a viscous gel and bind to cholesterol in the small intestine.
Beyond tailoring oat beta-glucan analysis to studies involving at least 3 g of oat beta-glucan daily, DSM’s new analysis also includes 10 studies, on about 1200 subjects, that were not yet published at the time of the last published meta-analysis. This data is now published in the American Journal of Clinical Nutrition.
Robby Gardner
Associate Editor
Nutritional Outlook magazine
robby.gardner@ubm.com
Photo © iStockphoto.com/masic75
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.